Investigating the role of inflammation markers in diagnosing immune thrombocytopenia
Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia
This study is testing if certain inflammation markers can help doctors diagnose immune thrombocytopenia more accurately in patients aged 1 to 50.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 1 Year to 50 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Sohag, Sahag) |
| Trial ID | NCT06715215 on ClinicalTrials.gov |
What this trial studies
This study focuses on immune thrombocytopenia (ITP), a condition characterized by low platelet counts due to antibody-mediated destruction. It aims to evaluate the role of acute phase proteins (APP), which are inflammation markers that change in concentration during inflammatory states, in the diagnosis of ITP. By analyzing these proteins, the study seeks to improve diagnostic accuracy for patients with ITP. The research will involve patients aged 1 to 50 years who meet specific inclusion criteria related to platelet counts and bone marrow findings.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 1 to 50 years with a platelet count of less than 100 × 10^9/L diagnosed with immune thrombocytopenia.
Not a fit: Patients with thrombocytopenia due to other causes, such as hypersplenism or bone marrow diseases, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnostic process for immune thrombocytopenia, leading to more accurate and timely treatment for patients.
How similar studies have performed: While the specific role of acute phase proteins in diagnosing ITP is not widely studied, similar approaches using inflammation markers have shown promise in other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with platelet less than 100 × 109/L diagnosed as immune thrombocytopenia by bone marrow findings . Age of patients : from 1 year to 50 years. Exclusion Criteria: * \- Other causes of thrombocytopenia as: * Hypersplenism. * Bone marrow diseases including : aplastic anemia, leukemia and myelodysplastic syndromes. * Cancer treatments like chemotherapy and radiation therapy. * Exposure to toxic chemicals as arsenic and benzene. * Medications to treat bacterial infections (antibiotics)and treat seizures or blood thinner heparin.
Where this trial is running
Sohag, Sahag
- Sohag university hospital — Sohag, Sahag, Egypt (Recruiting)
Study contacts
- Study coordinator: Rana M Abd Elhameed, Resident
- Email: rana_mohamed_post@med.sohag.edu.eg
- Phone: 01070198923
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.